Comment by rsfern

I don’t work in drug discovery, but isn’t this thought experiment skipping a lot of steps? My impression is AI is accelerating a lot of the preclinical screening and design work, but that’s pretty far from establishing “tremendously improved outcomes for patients” isn’t it? That’s still really difficult to verify, are people getting real acceleration of this part of the work with AI?